Organogenesis Holdings Inc
Company Profile
Business description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Contact
85 Dan Road
CantonMA02021
USAT: +1 781 575-0775
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
869
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.10 | 10.80 | -0.12% |
| CAC 40 | 8,210.52 | 48.34 | -0.59% |
| DAX 40 | 24,190.19 | 139.84 | -0.57% |
| Dow JONES (US) | 46,772.35 | 152.39 | -0.32% |
| FTSE 100 | 9,528.39 | 101.40 | 1.08% |
| HKSE | 25,781.77 | 245.78 | -0.94% |
| NASDAQ | 22,811.62 | 142.05 | -0.62% |
| Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
| NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
| S&P 500 | 6,713.35 | 22.00 | -0.33% |
| S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
| SSE Composite Index | 3,913.76 | 2.57 | -0.07% |